Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $93.7M | $96.2M | $103M | $118M | $134M | $184M | $219M | $216M | $241M | $249M |
| Revenue growth | — | 2.7% | 7.2% | 14.1% | 13.8% | 37.6% | 18.8% | -1.3% | 11.5% | 3.4% |
| Gross profit | $53.2M | $54.6M | $60.9M | $65.4M | $87.0M | $109M | $134M | $133M | $151M | $158M |
| Gross margin | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating income | $16.3M | $2.18M | $9.78M | $7.92M | $12.4M | $4.70M | $3.32M | -$272M | $16.3M | $18.5M |
| Operating margin | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Net income | — | — | — | — | $3.27M | $1.87M | $930K | -$254M | -$1.97M | $6.71M |
| Net margin | — | — | — | — | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| EPS (diluted) | $2.91 | -$0.79 | $1.86 | $0.41 | $0.64 | $0.35 | $0.17 | -$47.20 | -$0.36 | $1.21 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.3M | $25.7M | $30.6M | $27.0M | $37.1M | $39.2M | $28.0M | $44.1M | $46.8M | $42.8M |
| Capital expenditures | — | $2.80M | $1.26M | $1.50M | $1.99M | $4.43M | $4.54M | $2.57M | $4.25M | $3.25M |
| Free cash flow | — | $22.9M | $29.3M | $25.5M | $35.1M | $34.8M | $23.4M | $41.6M | $42.6M | $39.6M |
| Dividends paid | $2.35M | $2.41M | $2.46M | $2.72M | $3.17M | $3.34M | $3.41M | $3.45M | $3.47M | $3.52M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.82M | $5.47M | $10.2M | $81.4M | $264M | $49.3M | $32.9M | $28.2M | $27.3M | $26.9M |
| Total assets | $172M | $164M | $157M | $409M | $601M | $707M | $662M | $447M | $433M | $428M |
| Total liabilities | $73.9M | $64.7M | $45.5M | $189M | $195M | $314M | $268M | $301M | $274M | $242M |
| Long-term debt | $55.3M | $46.6B | $23.0M | — | — | — | — | — | $71.3M | $67.5M |
| Shareholders' equity | $97.8M | $99.4M | $111M | $220M | $406M | $394M | $393M | $145M | $160M | $186M |
| Retained earnings | $73.7M | $68.3M | $73.3M | $72.4M | $72.5M | $76.7M | $74.2M | -$183M | -$189M | -$186M |
| Shares (wtd avg diluted) | 3.84M | 3.77M | 4.03M | 4.37M | 5.12M | 5.33M | 5.36M | 5.39M | 5.42M | 5.57M |
Every figure is extracted from MESA LABORATORIES INC /CO/’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.